Nordic Capital announced an agreement to become the majority owner in Evosep, a leading Danish innovator of sample preparation and separation solutions for LC-MS-based proteomics. The investment, leveraging Nordic Capital’s experience as a leading investor in healthcare and life science for over 30 years, will be made in close collaboration with Evosep’s founders and management with the aim to accelerate the company’s global growth and support its mission to make proteomics more accessible and impactful through cutting-edge workflows, advanced analytics, and actionable insights.
Founded in 2016, Evosep has developed a technology that enables fast, robust and high-throughput protein analysis. The company develops cutting-edge instruments and consumables for reproducible liquid chromatography-mass spectrometry (LC-MS) based proteomics workflows, driving efficiency and scalability for translational research and biopharma applications. By simplifying complex proteomics processes, Evosep empowers laboratories to deliver deeper biological insights and accelerate discoveries that benefit modern healthcare and life sciences.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 November 2025
Nordic Capital’s investment in Evosep is based on its long-standing commitment to healthcare and diagnostics with deep expertise across biopharma, medtech and diagnostic technology, including successful investments in The Binding Site, Leo Pharma, Minerva Imaging, Equashield and Clario.
Health Technology Insights: Freenome Names Rob Guigley CCO as Exact Sciences Deal Clears
Building on Evosep’s strong position in proteomics, the partnership will focus on scaling the company’s platform to meet growing global demand for high-performance protein analysis, where consistent and comparable results are essential for biomarker discovery, disease understanding and diagnostic development. Working closely with Evosep’s founders and management team, Nordic Capital will provide strategic support to accelerate product development, enhance commercial capabilities and further expand Evosep’s presence in the proteomics market.
“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase. Together, we aim to redefine how proteomics drives efficiency, quality, and insight across healthcare and life sciences. Evosep’s mission remains set in stone, and customers can expect us to continue pushing forward the standardization of LCMS-based proteomics with impactful products and solutions,” said Morten Bern, CEO of Evosep.
“We are very impressed by Evosep’s highly innovative and differentiated technologies to enable and enhance proteomics analysis. The company enjoys a strong and loyal backing in both academia and biopharma. Nordic Capital intends to leverage its significant expertise in diagnostics and life science tools to support Morten and his team in further expanding the company’s reach and product offering,” said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.
The investment is made through Nordic Capital’s Evolution platform, which has a total committed capital of EUR 3.2 billion and targets investments in middle-market growth companies across Northern Europe. Applying the firm’s proven sector model, Evolution focuses on partnering with innovative businesses to scale internationally and create long-term value. Evosep represents the thirteenth investment announced by the Evolution platform since its launch in 2021.
As part of the transaction, minority shareholders EIFO and Novo Holdings will divest their respective shareholdings. The founders Ole Vorm and Matthias Mann will remain invested in Evosep.
Health Technology Insights: Hammes Healthcare Appoints Justin Franklin as VP in Denver
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
